• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

coronavirus

PharmaJet Tropis becomes exclusive intradermal delivery system for two COVID-19 vaccines

June 28, 2023 By Sean Whooley

PharmaJet Tropis needle-free intradermal injection system

PharmaJet announced that its Tropis system is now the exclusive intradermal delivery system for two novel COVID-19 vaccines. Golden, Colorado-based PharmaJet engineers precision delivery systems that overcome the challenges of nucleic acid vaccine delivery. Its Tropis system now offers the delivery of the world’s first plasmid DNA COVID-19 vaccine from Zydus Lifesciences. Exclusively delivered with […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, PharmaJet

Canadian university set for Phase 2 human trials of inhaled COVID-19 vaccine

January 20, 2023 By Sean Whooley

Researchers at McMaster University in Canada announced that they received $8.2 million from the Canadian Institutes of Health Research (CIHR). Fiona Smaill picked up $8.2 million to advance an inhaled COVID-19 vaccine through to Phase 2 human trials. The trials will evaluate the safety and immunogenicity of the next-generation vaccine delivered by inhaled aerosol. Her […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Research & Development, Respiratory Tagged With: coronavirus, COVID-19, McMaster University

Vaxxas receives more than $5 million grant for vaccine delivery patch

September 20, 2022 By Sean Whooley

Vaxxas micropatch vaccine COVID-19

Vaxxas announced today the Australian government is granting it nearly $5.5 million for the manufacturing of its vaccine delivery device. Cambridge, Massachusetts-based Vaxxas picked up AU$8.2 million ($5.48 million). The second-round grant represents part of the Australian government’s Modern Manufacturing Initiative (MMI). Funding supports the manufacturing scale-up of Vaxxas’ device for applying vaccines to the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, Vaxxas

Vaxxas licenses COVID-19 vaccine for patch delivery system, expects to finish Phase 1 trial this year

March 23, 2022 By Sean Whooley

Vaxxas micropatch vaccine COVID-19

Vaxxas announced today that it was granted an exclusive license for a next-generation COVID-19 vaccine to be used with its delivery patch. Cambridge, Massachusetts-based Vaxxas received the license from The University of Texas at Austin for its HexaPro SARS-CoV-2 spike subunit vaccine. The license comes with a companion background technology license from the U.S. National […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials Tagged With: coronavirus, COVID-19, University of Texas at Austin, Vaxxas

PharmaJet partner touts interim safety results for needle-free COVID-19 vaccine

February 15, 2022 By Sean Whooley

PharmaJet Stratis

PharmaJet announced today that its partner, Technovalia, reported positive interim safety results from a needle-free COVID-19 vaccine trial. Golden, Colorado-based PharmaJet’s needle-free injection systems are being studied with Covigen, a DNA-based vaccine developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with Melbourne, Australia-based Technovalia. Enrollment for the trial began in June 2021. The Phase 1 […]

Filed Under: Auto-injectors, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, PharmaJet

Could nasal vaccines be the next big weapon against COVID-19?

February 3, 2022 By Sean Whooley

Mucosa and relevant structures

Because of the way they provide protection, nasal vaccines could be the best long-term way to prevent COVID-19 infection, according to experts cited in The New York Times. The Times reported that India-based Bharat Biotech, which has the Covaxin COVID-19 vaccine authorized in India and elsewhere, has an experimental COVID-19 nasal vaccine that may offer […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Bharat Biotech, coronavirus, COVID-19

PharmaJet partner announces COVID-19 vaccine trial with needle-free injection tech

December 14, 2021 By Sean Whooley

PharmaJet Stratis

PharmaJet announced today that one of its pharmaceutical partners, Nykode Therapeutics, has begun a trial for a COVID-19 vaccine with PharmaJet’s needle-free injection technology. Nykode’s Phase 1/2 clinical trial will specifically address the emerging SARS-CoV-2 variants, with the DNA-based vaccines delivered intramuscularly with PharmaJet’s Stratis needle-free injection system. The vaccines are designed to be tailored […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, PharmaJet

Aerogen inks partnership to deliver COVID-19 vaccine with its mesh aerosol delivery tech

December 13, 2021 By Sean Whooley

Aerogen_Solo CanSinoBio

Aerogen and CanSinoBio announced today that they entered a partnership to deliver the latter’s COVID-19 vaccine with Aerogen’s technology. Galway, Ireland-based Aerogen’s proprietary vibrating mesh aerosol drug delivery technology will be used to deliver CanSinoBio’s recombinant novel coronavirus vaccine — Convidecia — under the development and commercial supply partnership. Commercial terms for the partnership were […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Aerogen, CanSinoBio, coronavirus, COVID-19

World faces a shortage of up to 2 billion COVID-19 vaccine syringes

November 9, 2021 By Sean Whooley

Pfizer COVID-19 vaccine

The World Health Organization (WHO) reportedly warned that a massive shortage of syringes for COVID-19 vaccines could be on the horizon. Reuters reported that WHO  expert Lisa Hedman told a United Nations briefing that the potential shortage of 1 billion to 2 billion syringes could slow down routine immunizations and create issues with needle safety […]

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, UNICEF, World Health Organization

BD ticks up on Street-beating Q4, sets 2022 guidance range

November 4, 2021 By Sean Whooley

This is the logo of BD.

BD (NYSE:BDX) shares rose today on fourth-quarter results that came in ahead of the consensus forecast. The Franklin Lakes, New Jersey-based medtech posted profits of $242 million, or 84¢ per share, on sales of $5.1 billion for the three months ended Sept. 30, 2021, more than doubling its bottom line on sales growth of 7.3%. Get […]

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: BD, coronavirus, COVID-19

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 6
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS